# Mechanistic Hypotheses: BBB Permeability as Early Neurodegeneration Biomarker
---
## Hypothesis 1: Caveolin-1-Mediated Transcytosis Upregulation Precedes Paracellular Tight Junction Loss in Early AD
**Mechanism:** In early Alzheimer's disease (AD), loss of pericytes triggers compensatory upregulation of caveolin-1 (CAV1)-dependent transcytosis as a rapid-response permeability mechanism, *prior to* structural disruption of claudin-5/occluden-based tight junctions. This creates a "leaky sieve" phenotype where low-molecular-weight proteins (<10 kDa) cross the BBB via transendothelial vesicles while large molecules remain restricted. The transcytotic shift represents a mechanistically distinct early BBB failure mode from the paracellular route more commonly studied.
**Key Evidence:**
- Day et al. (2015) demonstrated in aged mice and postmortem AD human tissue that CAV1 expression inversely correlates with pericyte coverage and directly correlates with BBB permeability to low-molecular-weight tracers (PMID: 26387538).
- Montagne et al. (2015) showed that pericyte degeneration accounts for ~85% of BBB breakdown in AD models, with increased vesicular transport evident before overt tight junction protein loss (PMID: 26341246).
**Testable Prediction:** In a longitudinal cohort of cognitively normal elderly with elevated amyloid PET but no neurodegeneration, baseline CSF/plasma ratios of low-molecular-weight markers (S100B: ~10 kDa) relative to high-molecular-weight markers (albumin: 66 kDa; IgG: 150 kDa) will predict conversion to MCI at 3-year follow-up. Specifically, elevated S100B/albumin CSF/serum ratio—reflecting transcytosis dominance—will outperform elevated albumin ratio alone (which reflects paracellular leak). Falsification: If both ratios show identical predictive values, transcytosis and paracellular permeability are coupled events rather than sequential.
**Target Protein:** Caveolin-1 (CAV1) — endothelial lipid raft protein regulating caveolae-mediated transcytosis
---
## Hypothesis 2: Sleep-Dependent Glymphatic Interstitial Fluid Clearance Failure Triggers Pericyte PDGFR-β Cleavage Cascade
**Mechanism:** Impaired sleep quality—common in aging and early neurodegeneration—reduces glymphatic arterial pulsation-driven interstitial fluid clearance, causing Aβ/tau accumulation in perivascular Virchow-Robin spaces. This accumulation activates astrocyte-derived MMP-9, which proteolytically cleaves PDGFR-β on pericytes, releasing soluble PDGFR-β (sPDGFR-β) into CSF. sPDGFR-β functions as a dominant-negative inhibitor of PDGF-BB signaling, perpetuating pericyte detachment. This creates a feedforward loop: clearance failure → pericyte stress → worsened clearance.
**Key Evidence:**
- Iliff et al. (2013) established that glymphatic CSF-ISF exchange is regulated by norepinephrine-mediated astrocyte contractility and declines during wakefulness and with aging (PMID: 24136970).
- Sweeney et al. (2016) demonstrated that pericyte loss in AD correlates with impaired glymphatic perfusion and perivascular Aβ deposition, with sPDGFR-β elevated in AD CSF (PMID: 26709156).
**Testable Prediction:** In a sleep-polysomnography-monitored cohort, subjects with reduced slow-wave sleep (<10% of total sleep time) and elevated CSF sPDGFR-β at baseline will show accelerated cortical atrophy in perivascular regions (particularly along penetrating arterioles in frontal cortex) on 2-year longitudinal MRI, independent of amyloid/tau status. Falsification: If cortical atrophy pattern does not preferentially localize to perivascular zones in high sPDGFR-β/low slow-wave sleep individuals, the glymphatic-pericyte mechanistic link is not supported.
**Target Protein:** PDGFR-β (membrane-bound) → proteolytic cleavage generates soluble sPDGFR-β; MMP-9 as upstream protease
---
## Hypothesis 3: Astrocyte-Secreted miR-132/212 Cluster Nanovesicles Epigenetically Suppress Claudin-5 Translation in Pre-Symptomatic Neurodegeneration
**Mechanism:** Astrocyte end-feet release extracellular nanovesicles (ANVs) containing microRNA-132/212 cluster members (particularly miR-132), which are taken up by brain microvascular endothelial cells (BMVECs). In neurodegeneration-prone states, astrocyte inflammatory activation (via NF-κB pathway) causes selective enrichment of miR-132 in ANVs.